1. patients on other interventional clinical trials 2. subjects diagnosed with congestive or unstable heart disease including heart failure, left ventricular dysfunction (lvef \< 40 %) or myocardial damage, severe pulmonary hypertension and/or unstable hypertension 3. subjects diagnosed with immunodeficiency 4. hematology: patients with clinically significant anemia e.g. hemoglobin \< 100 and thrombocytopenia e.g. platelets \< 75 5. subjects with clinically significant history of, or active bleeding including active pulmonary or gastrointestinal bleeding 6. hepatic function: patients with abnormal liver function defined as any two of the following alt \>3x uln, ast \>3x uln, total bilirubin \< 1.5 x uln 7. patient receiving drugs that have a contraindication with no e.g. use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as lidocaine, prilocaine, benzocaine or dapsone at screening as relevant to the proposed study population 8. pregnancy 9. subjects with a known hypersensitivity to methylene blue, subjects with glucose-6-phosphate dehydrogenase (g6pd) deficiency 10. known or suspected thalassemia, sickle cell disease, or other conditions associated with poor oxygen carrying capacity

1. patients on other interventional clinical trials 2. subjects diagnosed with congestive or unstable heart disease including heart failure, left ventricular dysfunction (lvef \< 40 %) or myocardial damage, severe pulmonary hypertension and/or unstable hypertension 3. subjects diagnosed with immunodeficiency 4. hematology: patients with clinically significant anemia e.g. hemoglobin \< 100 and thrombocytopenia e.g. platelets \< 75 5. subjects with clinically significant history of, or active bleeding including active pulmonary or gastrointestinal bleeding 6. hepatic function: patients with abnormal liver function defined as any two of the following alt \>3x uln, ast \>3x uln, total bilirubin \< 1.5 x uln 7. patient receiving drugs that have a contraindication with no e.g. use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as lidocaine, prilocaine, benzocaine or dapsone at screening as relevant to the proposed study population 8. pregnancy 9. subjects with a known hypersensitivity to methylene blue, subjects with glucose-6-phosphate dehydrogenase (g6pd) deficiency 10. known or suspected thalassemia, sickle cell disease, or other conditions associated with poor oxygen carrying capacity

patients on other interventional clinical trials subjects diagnosed with congestive or unstable heart disease including heart failure, left ventricular dysfunction (lvef < 40 %) or myocardial damage, severe pulmonary hypertension and/or unstable hypertension subjects diagnosed with immunodeficiency hematology: patients with clinically significant anemia e.g. hemoglobin < 100 and thrombocytopenia e.g. platelets < 75 subjects with clinically significant history of, or active bleeding including active pulmonary or gastrointestinal bleeding hepatic function: patients with abnormal liver function defined as any two of the following alt >3x uln, ast >3x uln, total bilirubin < 1.5 x uln patient receiving drugs that have a contraindication with no e.g. use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as lidocaine, prilocaine, benzocaine or dapsone at screening as relevant to the proposed study population pregnancy subjects with a known hypersensitivity to methylene blue, subjects with glucose-6-phosphate dehydrogenase (g6pd) deficiency known or suspected thalassemia, sickle cell disease, or other conditions associated with poor oxygen carrying capacity

patients on other interventional clinical trials subjects diagnosed with congestive or unstable heart disease including heart failure, left ventricular dysfunction (lvef < 40 %) or myocardial damage, severe pulmonary hypertension and/or unstable hypertension subjects diagnosed with immunodeficiency hematology: patients with clinically significant anemia e.g. hemoglobin < 100 and thrombocytopenia e.g. platelets < 75 subjects with clinically significant history of, or active bleeding including active pulmonary or gastrointestinal bleeding hepatic function: patients with abnormal liver function defined as any two of the following alt >3x uln, ast >3x uln, total bilirubin < 1.5 x uln patient receiving drugs that have a contraindication with no e.g. use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as lidocaine, prilocaine, benzocaine or dapsone at screening as relevant to the proposed study population pregnancy subjects with a known hypersensitivity to methylene blue, subjects with glucose-6-phosphate dehydrogenase (g6pd) deficiency known or suspected thalassemia, sickle cell disease, or other conditions associated with poor oxygen carrying capacity

1. patients on other interventional clinical trials 2. subjects diagnosed with congestive or unstable heart disease including heart failure, left ventricular dysfunction (lvef < 40 %) or myocardial damage, severe pulmonary hypertension and/or unstable hypertension 3. subjects diagnosed with immunodeficiency 4. hematology: patients with clinically significant anemia e.g. hemoglobin < 100 and thrombocytopenia e.g. platelets < 75 5. subjects with clinically significant history of, or active bleeding including active pulmonary or gastrointestinal bleeding 6. hepatic function: patients with abnormal liver function defined as any two of the following alt >3x uln, ast >3x uln, total bilirubin < 1.5 x uln 7. patient receiving drugs that have a contraindication with no e.g. use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as lidocaine, prilocaine, benzocaine or dapsone at screening as relevant to the proposed study population 8. pregnancy 9. subjects with a known hypersensitivity to methylene blue, subjects with glucose-6-phosphate dehydrogenase (g6pd) deficiency 10. known or suspected thalassemia, sickle cell disease, or other conditions associated with poor oxygen carrying capacity

1. patients on other interventional clinical trials 2. subjects diagnosed with congestive or unstable heart disease including heart failure, left ventricular dysfunction (lvef < 40 %) or myocardial damage, severe pulmonary hypertension and/or unstable hypertension 3. subjects diagnosed with immunodeficiency 4. hematology: patients with clinically significant anemia e.g. hemoglobin < 100 and thrombocytopenia e.g. platelets < 75 5. subjects with clinically significant history of, or active bleeding including active pulmonary or gastrointestinal bleeding 6. hepatic function: patients with abnormal liver function defined as any two of the following alt >3x uln, ast >3x uln, total bilirubin < 1.5 x uln 7. patient receiving drugs that have a contraindication with no e.g. use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as lidocaine, prilocaine, benzocaine or dapsone at screening as relevant to the proposed study population 8. pregnancy 9. subjects with a known hypersensitivity to methylene blue, subjects with glucose-6-phosphate dehydrogenase (g6pd) deficiency 10. known or suspected thalassemia, sickle cell disease, or other conditions associated with poor oxygen carrying capacity